RELEASES
-
For further information contact:
Fred Iannotti
802-888-0085
fiannotti@planningsource.comNov. 29-Dec. 2 Greater NY Dental Meeting To Feature Award-Winning Identafi 3000 Ultra
Trimira Booth #5029 to Demo First and Only Device to Use "Multispectral" Technology to Detect Deadly Oral Cancer
DEMO:
Demonstrations of Trimira® LLC's "multispectral" Identafi® 3000 ultra will spotlight the world's first and only "multispectral" oral cancer detection device. Early detection is vital in curing oral cancer. Identafi® 3000 ultra uses optical reflectance and fluorescence technologies — specifically, white, violet, and green-amber lightwaves — to excite oral tissue in distinct ways, enabling dentists and doctors to catch early indicators and stages of oral cancer and pre-cancer that are missed by the naked eye.WHY:
Oral cancer kills someone every hour of every day. It is more deadly (in terms of five-year mortality rate) than breast, cervical, colon, kidney, thyroid, liver, or prostate cancers. Fully 40 percent of those diagnosed with oral cancer will be dead in five years. Early detection through regular screenings, however, would improve the survival rate to 80-90 percent.WHAT: Identafi® 3000 ultra is a powerful handheld that incorporates advances in cancer detection from research scientists at The University of Texas Rice University, and British Columbia Cancer Research Centre. Early detection of oral cancer translates into cure rates of greater than 80 percent, which is why American Cancer Society (ACS) and American Dental Association (ADA) recommend opportunistic screening for oral cancer. ADA estimates that while 60 percent of Americans visit a dentist every year, few of those who regularly visit a dentist get screened.
WHERE:
Booth #5029 — Trimira® LLC;
Jacob K. Javits Convention Center, 655 West 34th Street, New York City.WHO:
Trimira® LLC VP, Marketing Jerry S. Trzeciak (cell: 281-793-3038)WHEN:
Sunday, November 29;
Monday, November 30;
Tuesday, December 1;
Wednesday, December 2.IDENTAFI:
TRIMIRA:
Identafi® 3000 ultra is the most accurate intraoral tool for screening patients for signs of oral cancer. The next-generation device features high-speed, high-resolution optical processing technologies that are changing the diagnostic landscape. Created expressly for dentists, primary-care physicians, periodontists, otolaryngologists, and oral surgeons, Trimira® LLC's cordless Identafi® 3000 ultra is ergonomically shaped, as well as small, lightweight, and portable. Because it is portable, the handheld may be readily moved from room to room and patient to patient. It incorporates a new nickel-plated design that improves durability and delivers a smoother feel. Identafi® 3000 ultra's violet wavelength capability was cited in the May 2009 issue of Cancer Prevention Research, the journal of the American Association for Cancer Research, as the best excitation wavelength to discriminate between neoplastic and non-neoplastic tissue areas. Identafi® 3000 ultra delivers a higher degree of clinical accuracy and confidence to users, which translates into better patient care.
Trimira® LLC is venture capital-funded by cancer research philanthropist T. Boone Pickens, of oil and windfarming fame. Trimira's sister subsidiaries are developing screening and diagnostic devices for skin, cervical, bladder, and gastrointestinal cancers. Remicalm® LLC, the parent company, has licensed exclusive use of certain of its patents and patents pending for use as a cervical cancer product to be later expanded to include additional epithelial-based cancers. Remicalm's core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy human tissue.Visit Trimira® at: http://www.trimira.net/
Animations
Identafi® Technology
Identafi® Process
Screening Results
Training
